- ►ecmaj.com DB Hogan, P Bailey, S Black, A Carswell, H … - Canadian Medical Association Journal, 2008 - ecmaj.com From the Departments of Medicine and Clinical Neurosciences (Hogan), University
of Calgary, Calgary, Alta.; the Division of Neurology, Department of Medicine
(Bailey), the School of Occupational Therapy (Carswell), the Department of ... Cited by 6 - Related articles - All 14 versions
LY Park-Wyllie, MM Mamdani, P Li, SS Gill, A …, 2009 - pubmedcentral.nih.gov ICMJE criteria for authorship read and met: LPW MMM PL SSG AL DNJ. Agree with
the manuscript's results and conclusions: LPW MMM PL SSG AL DNJ. Designed the
experiments/the study: LPW MMM SSG AL DNJ. Analyzed the data: LPW PL SSG. ... Cited by 2 - Related articles - All 4 versions
J Grace, MM Amick, JH Friedman - British Medical Journal, 2009 - jnnp.bmj.com Methods: Sixty-nine non-demented PD participants were randomised in a
double-blind, placebo-controlled study of galantamine or placebo. Galantamine
was administered over 16 weeks (8 mg/day for 4 weeks, a therapeutic dose of ... Cited by 1 - Related articles - All 4 versions
AD Dangour, E Allen, D Elbourne, A Fletcher, … - The Journal of Nutrition, Health and Aging, 2009 - Springer Cognitive impairment in later life is a recognised risk factor for the
development of dementia (1). Currently available pharmacological treatments for
dementia are only modestly effective and very expensive (2), and there is ... Cited by 1 - Related articles - All 2 versions
MW Riepe, B Ibach - Dement Geriatr Cogn Disord, 2008 - content.karger.com Dementia is one of the most common diseases of old age [1] affecting up to 20%
of the population depending on age and diagnostic criteria [2] . The most common
cause of dementia is Alzheimer's disease (AD) [3] . AD presents with memory ... Cited by 1 - Related articles - All 4 versions
P Fuentes - Current Hypotheses and Research Milestones in …, 2009 - Springer Abstract At the moment, we have five formally approved anti-dementia drugs. It
is well known that abnormalities in cholinergic neurons are prominent among the
pathological changes in the brains of patients with Alzheimer's disease ... Related articles - All 2 versions
S Gauthier, J Poirier - Alzheimer's & Dementia: The Journal of the Alzheimer's …, 2009 - Elsevier The concept of disease modification for Alzheimer's disease (AD) means different
things to different people, as summarized in Table 1. For instance, an
asymptomatic person at higher risk because of a family history of AD in a ... Related articles - All 16 versions
K Rockwood, S Fay, M Gorman - International journal of geriatric psychiatry, 2009 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Related articles - All 2 versions
[CITATION] Last literature review version 17.1: Thu Jan 01 00: 00: 00 GMT 2009| This topic last …
D Pipeline&News - Prevention, 2008 - caremark.com Capsule(s); 200 mg Treatment of chronic phase and accelerated phase Philadelphia
chromosome-positive chronic myelogenous leukemia (CML) in adult patients
resistant or intolerant to prior therapy that included Gleevec® (imatinib, ... Related articles - View as HTML - All 4 versions
